Supernus Pharmaceuticals (SUPN) Capital Expenditures Growth (1y) (2012 - 2025)
Supernus Pharmaceuticals (SUPN) Capital Expenditures Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn | -21.54% |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100.47% |
| Sep 30, 2025 | -35.50% |
| Jun 30, 2025 | 610.94% |
| Mar 31, 2025 | 31.85% |
| Dec 31, 2024 | 691.67% |
| Sep 30, 2024 | 33.33% |
| Jun 30, 2024 | -59.75% |
| Mar 31, 2024 | -10.79% |
| Dec 31, 2023 | 78.57% |
| Jun 30, 2023 | 412.90% |
| Mar 31, 2023 | -49.36% |
| Dec 31, 2020 | -91.71% |
| Sep 30, 2020 | 255.77% |
| Mar 31, 2020 | 1,194.39% |
| Dec 31, 2019 | 2,603.13% |
| Sep 30, 2019 | -125.62% |
| Jun 30, 2019 | -44.94% |
| Mar 31, 2019 | -22.53% |
| Dec 31, 2018 | -87.30% |
| Sep 30, 2018 | -3.56% |